Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet

Qin, Chao; He, Wei; Zhu, Chunli; Wu, Mengmeng; Zhu, Jin; Zhang, Qiang; Wang, Guangji; Yin, Lifang

doi:10.1016/j.ijpharm.2014.03.002

Cited by 34 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicated that there was a good correlation between in vitro release and in vivo absorption of M15-80 prepared by thermoplastic coating, therefore the in vivo drug absorption could be predicted by in vitro drug release. 10,11 Pharmacokinetic Study of HHL-NIF…”

Section: In Vitro-in Vivo Correlationmentioning

confidence: 99%

New Technology of Thermoplastic Coating for Osmotic Pump Tablets: Study on in vivo Drug Release

Yuan

Hou

Cheng

et al. 2020

Pharmaceutical Fronts

View full text Add to dashboard Cite

Abstract Aim The in vivo pharmacokinetics of thermoplastic-coated tablets prepared by a new technology of thermoplastic coating in Beagle dogs were studied, and the correlation between in vitro release and in vivo absorption was analyzed. Methods The in vitro release profiles of metformin hydrochloride thermoplastic-coated tablets and nifedipine thermoplastic-coated tablets were investigated. The single-dose pharmacokinetic study of these tablets in Beagle dogs was performed, and the obtained results were separately compared with the data of conventional osmotic pump tablets reported in the literature. Results Metformin hydrochloride thermoplastic-coated tablets and nifedipine thermoplastic-coated tablets displayed controlled drug-release characteristics and had a good in vivo–in vitro correlation in Beagle dogs, respectively. The literature-compared results further demonstrated that both thermoplastic-coated tablets had release characteristics of osmotic pump tablets in vivo. Conclusion The thermoplastic-coated tablets could control drug release in vivo and it was further confirmed that the new thermoplastic coating technology could replace the spray coating of osmotic pump controlled-release tablets. This study provides a theoretical basis and practical support for the industrialization and clinical application of the new thermoplastic coating technology.

show abstract

Section: In Vitro-in Vivo Correlationmentioning

confidence: 99%

New Technology of Thermoplastic Coating for Osmotic Pump Tablets: Study on in vivo Drug Release

Yuan

Hou

Cheng

et al. 2020

Pharmaceutical Fronts

View full text Add to dashboard Cite

show abstract

“…Before the granulation process, the drug and other raw materials were dried at 60°C for 2 h and then passed through an 18-mesh screen (14).…”

Section: Preparation Of Sustained Release Bilayer Tabletsmentioning

confidence: 99%

“…To overcome the drawbacks of combination IR formulation of MH and RG, we previously reported a sandwiched osmotic pump system for the two drugs, which both of them were released at a zero-order rate (14); however, the preparation process was too complicated to scale up. Thus, a new dosage form that is prepared by a more simple process and continuously releases the two drugs over time is required.…”

Section: Introductionmentioning

confidence: 99%

Bilayer Matrix Tablets for Prolonged Actions of Metformin Hydrochloride and Repaglinide

Huang

Zhou

et al. 2014

AAPS PharmSciTech

Self Cite

View full text Add to dashboard Cite

A combination therapy of metformin hydrochloride (MH) and repaglinide (RG) achieves a perfect glycemic control; however, the combination formulation of immediate release must be taken several times a day, compromising the therapeutic benefits and causing inconveniences to the patients. Herein, a bilayer matrix tablet that aimed at continuously releasing both MH and RG over time was developed, in which the two drugs were formulated into two separated layers. The tablets were prepared by wet granulation method, and the optimized formulation was obtained by evaluating the factors that affected the drug release. The bilayer tablets simultaneously released the two drugs over 12 h; and a better in vivo performance with a steady plasma concentration, markedly lower Cmax, prolonged Tmax, and perfect absorption was obtained. Summarily, the bilayer matrix tablets sustained both MH and RG release over time, thereby prolonging the actions for diabetic therapy and producing better health outcomes.

show abstract

“…For example, simultaneously delivery of two or three drugs with different solubility was realized in a sandwiched osmotic pump tablet system, which consisted of a push layer and two attached drug layers on the opposite sides surrounded with a semi-membrane with two orifices on each side 11,12,13 . In another two examples, the co-delivery of metformin J U S T A C C E P T E D hydrochloride and glipizide were realized with a newly developed inlay osmotic pump tablet through including glipizide into HP-β-CD 14 and a modified push-pull osmotic system 15 , respectively.…”

Section: Introductionmentioning

confidence: 99%

“…Felodipine is released by erosion of the gel matrix and metoprolol release is controlled by the diffusion rate through a polymeric membrane which surrounds each individual pellet 16 . That is, two or more sophisticated strategies are applied in most cases to achieve controlled release for drugs with completely different solubility, which means complex ingredients and sophisticated techniques 12,17 .…”

Section: Introductionmentioning

confidence: 99%

Synchronous delivery of felodipine and metoprolol tartrate using monolithic osmotic pump technology

Zhao¹,

Yu²,

Liu³

et al. 2016

Drug Development and Industrial Pharmacy

View full text Add to dashboard Cite

The synchronous sustained-release of two drugs was desired urgently for patients needing combination therapy in long term. However, sophisticated technologies were used generally to realize the simultaneous delivery of two drugs especially those with different physico-chemical properties. The purpose of this study was to obtain the concurrent release of felodipine and metoprolol tartrate, two drugs with completely different solubilities, in a simple monolithic osmotic pump system (FMOP). Two types of blocking agents were used in monolithic osmotic pump tablets and the synchronous sustained-release of FMOP was acquired in vitro. The tablets were also administered to beagle dogs and the plasma levels of FMOP were determined by HPLC-MS/MS. The pharmacokinetic parameters were calculated using a non-compartmental model. Cmax of both felodipine and metoprolol from the osmotic pump tablets were lower, tmax and mean residence time of both felodipine and metoprolol from the osmotic pump tablets were longer significantly than those from immediate release tablets. These results verified prolonged release of felodipine and metoprolol tartrate from osmotic pump formulations. The similar absorption rate between felodipine and metoprolol in beagles was also obtained by this osmotic pump formulation. Therefore, it could be supposed that the accordant release of two drugs with completely different solubilities may be realized just by using monolithic osmotic pump technology.

show abstract

Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet

Cited by 34 publications

References 25 publications

New Technology of Thermoplastic Coating for Osmotic Pump Tablets: Study on in vivo Drug Release

New Technology of Thermoplastic Coating for Osmotic Pump Tablets: Study on in vivo Drug Release

Bilayer Matrix Tablets for Prolonged Actions of Metformin Hydrochloride and Repaglinide

Synchronous delivery of felodipine and metoprolol tartrate using monolithic osmotic pump technology

Contact Info

Product

Resources

About